At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 50 enrolled
Drug / intervention
bevacizumabbiological
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Phase II Trial of Bevacizumab in Patients With Recurrent or Progressive Meningiomas
In Brief
A Phase 2 clinical trial evaluating bevacizumab for Acoustic Schwannoma and 9 related conditions. Completed, enrolled 50 participants across 5 sites.
Detailed Summary
RATIONALE: Monoclonal antibodies, such as bevacizumab, can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread. Others find tumor cells and help kill them or carry tumor-killing substances to them. PURPOSE: This phase II trial is studying how well bevacizumab works in treating patients with recurrent or progression meningiomas.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAcoustic Schwannoma, Adult Anaplastic Meningioma, Adult Ependymoma, Adult Grade I Meningioma, Adult Grade II Meningioma, Adult Meningeal Hemangiopericytoma, Adult Papillary Meningioma, Neurofibromatosis Type 1, Neurofibromatosis Type 2, Recurrent Adult Brain Tumor
CountriesUnited States
Collaborators--
Timeline
Phase 2CompletedFinished
20102011201220132014201520162017201820192020202120222023202420252026
First PostedMay 2010
Enrollment StartJun 2010
Primary CompletionMar 2014
Study CompletionDec 2018
TodayJul 2026
First PostedMay 18, 2010
Enrollment StartJun 17, 2010
Primary CompletionMar 10, 2014
Study CompletionDec 31, 2018
TodayJul 2, 2026
Enrollment to primary: 3.7 yearsPosted 16.1 years ago
Interventions
bevacizumabbiological
Given IV